YES1 and breast carcinoma: Given the implication of these results for the treatment of breast cancer patients with pan-SFK inhibitors, we next investigated the involvement of individual SFK members (c-Src, Fyn, Yes or Lyn) in the regulation of Claudin-2 expression.